Last Updated: July 2, 2026

SUFENTANIL Drug Patent Profile

Name: SUFENTANIL Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Sufentanil, and what generic alternatives are available?

Sufentanil is a drug marketed by Hikma, Hospira, and Watson Labs. and is included in three NDAs.

The generic ingredient in SUFENTANIL is sufentanil citrate. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the sufentanil citrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sufentanil

A generic version of SUFENTANIL was approved as sufentanil citrate by HOSPIRA on December 11^th, 1996.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for SUFENTANIL?
What are the global sales for SUFENTANIL?
What is Average Wholesale Price for SUFENTANIL?

Summary for SUFENTANIL

US Patents:	0
Applicants:	3
NDAs:	3
DailyMed Link:	SUFENTANIL at DailyMed

Drug patent expirations by year for SUFENTANIL

US Patents and Regulatory Information for SUFENTANIL

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	SUFENTANIL CITRATE	sufentanil citrate	INJECTABLE;INJECTION	074413-001	Dec 15, 1995		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Hospira	SUFENTANIL CITRATE	sufentanil citrate	INJECTABLE;INJECTION	074534-001	Dec 11, 1996	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Watson Labs	SUFENTANIL CITRATE	sufentanil citrate	INJECTABLE;INJECTION	074406-001	Dec 15, 1995		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.